Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BMEA with free AI briefings, catalyst countdowns, and dilution alerts.

BMEA · Biomea Fusion, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$26.4M Cash on Hand
8.6mo Cash Runway
Follow BMEA by email Get an email when BMEA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BMEA, unsubscribe in one click. Privacy

📣 What BMEA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Icovamenib (BMF-219) Type 2 Diabetes Mellitus Phase 1/2 · NCT05731544 Completed
FLT3 Inhibitor BMF-500 Acute Myeloid Leukemia Phase 1 · NCT05918692 Completed
BMF-650 Obesity Phase 1 · NCT07223216 Completed
Icovamenib HPMC Healthy Volunteer Phase 1 · NCT07254286 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BMEA holds $26.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.2M/quarter from operations, an estimated runway of 8.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BMEA files for a raise →

👥 Who Owns BMEA

Insiders 7.7% Other 5%+ holders 16.9% Institutions (74 holders) 39.3% Public and other holders 36.1%
HolderTypeShares% of sharesAs of
CVI Investments, Inc. 5%+ holder (13G) 7,847,232 10.80% 2025-12-31
Blue Owl Capital Holdings LP 5%+ holder (13G) 4,451,219 6.12% 2025-12-31
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 3,750,000 5.16% 2025-11-28
Bihua Chen
Former Director · +202,762 options
Insider 3,570,872 4.91% 2025-08-01
Rainer M Erdtmann
Officer, Director · +1.84M options
Insider 1,847,416 2.54% 2025-12-31
Michael J.M. Hitchcock
Interim CEO, Director · +1.98M options
Insider 115,000 0.16% 2025-12-02
Franco Valle
Chief Financial Officer · +145,245 options
Insider 42,995 0.06% 2024-11-30
Juan Pablo Frias
Chief Medical Officer · +111,090 options
Insider 349 0.00% 2024-05-31

Share count 72,678,080 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BMEA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMEA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.